Compare ADPT & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | WRBY |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2019 | 2021 |
| Metric | ADPT | WRBY |
|---|---|---|
| Price | $13.56 | $28.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $17.78 | ★ $27.10 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 105.88 |
| EPS | N/A | ★ 0.03 |
| Revenue | $276,976,000.00 | ★ $871,905,000.00 |
| Revenue This Year | $3.98 | $14.48 |
| Revenue Next Year | $22.72 | $16.41 |
| P/E Ratio | ★ N/A | $984.00 |
| Revenue Growth | ★ 54.77 | 13.04 |
| 52 Week Low | $8.50 | $14.96 |
| 52 Week High | $20.76 | $31.00 |
| Indicator | ADPT | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 66.97 |
| Support Level | $12.22 | $21.22 |
| Resistance Level | $15.38 | $31.00 |
| Average True Range (ATR) | 0.79 | 1.77 |
| MACD | -0.02 | 0.71 |
| Stochastic Oscillator | 27.88 | 88.78 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.